Prophylaxis with concentrates of factor VIII has become the standard of care for patients with
severe haemophilia A because of its ability to prevent joint and other bleeding events …

In patients with severe haemophilia and inhibitors, regular factor VIII inhibitor bypassing
activity (FEIBA) prophylaxis has been shown to reduce the frequency of bleeding by up to …

Background: Hemophilic patients with factor VIII (FVIII) and FIX inhibitors suffer from frequent
bleeding episodes and reduced quality of life. Objectives: To evaluate whether secondary …

Persistent high‐titre inhibitors after immune tolerance induction (ITI) increase the risks of
haemorrhage and arthropathy, resulting in high morbidity and mortality. Long‐term …

Factor replacement therapy for the treatment of moderate to severe haemophilia A and B
can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor …

INTRODUCTION: Hemophilia patients with inhibitors have frequent bleeding episodes and
often develop hemophilic arthropathy which is in contradistinction to non-inhibitor patients …

Prophylaxis with clotting factor concentrates has been shown to prevent bleeding episodes
and improve quality of life in patients with severe haemophilia A or B. The benefits of long …

An antibody response to therapeutically administered factor VIII (FVIII) can occur in up to
30% of patients with haemophilia, resulting in the production of inhibitors that neutralize FVIII …

Background: Prophylaxis with factor (F) VIII is considered the optimal treatment for managing
hemophilia A patients without inhibitors. Objectives: To compare the efficacy of two …

Prophylaxis with the blood clotting factor, factor VIII (FVIII) is ineffective for individuals with
haemophilia A and high-titre inhibitors to FVIII. Prophylaxis with the FVIII bypassing agents …